AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 82 min read$PTCT

Almstead Neil Gregory sold $4.1M of PTCT

Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER) sold 46,774 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $87.52 ($85.28–$89.44, $4.09M total) across 8 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Almstead Neil Gregory
Published Jul 8, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Neutral
medium confidence
Mentioned
$PTCT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTNeutralLow
01

Why it matters

The newest concrete fact is the officer’s open-market sale of 46,774 shares at a weighted average price of $87.5162, totaling $4,093,481.61, with holdings after the transaction of 60,299 shares.

02

Market read

Useful for tracking insider behavior in PTCT, but it does not provide new clinical, regulatory, or guidance information.

03

What to watch

Traders may want to compare this sale to prior insider transactions and whether holdings after the sale remain large enough to matter for signaling.

Relevance 5/10Novelty 6/10Timing: after-hours/filing update on 2026-07-08

Background

The article is an SEC Form 4 insider transaction disclosure for PTC Therapeutics, filed 2026-07-08.

Company-level read

Ticker impact

$PTCTNeutralMedium confidence
Context

PTCT insider Almstead Neil Gregory, Chief Technical Ops Officer, sold about $4.09M of shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; more relevant for monitoring insider activity than for fundamentals.

Evidence & confidence

The filing is a Form 4 showing a multi-trade sale ($4.09M) by an officer, explicitly under a pre-arranged 10b5-1 plan, which typically reduces the signal of new negative information.

Market effects

Sector

Minimal sector read-through; this is company-specific insider activity without any disclosed regulatory, clinical, or product catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than a change in outlook, so the market reaction may be overstated.

Key entities

  • issuer
    PTC THERAPEUTICS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Almstead Neil Gregory

    Chief Technical Ops Officer who sold shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan noted as Yes, which typically reduces interpretive signal.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

AUG 27
$PTCTMedAI 8/10

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

simplywall.st3 min
AUG 24
$PTCTMedAI 8/10

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

morningstar.com2 min
AUG 24
$PTCTMedAI 8/10

PTC presents Sephience data at metabolic disorders symposium

PTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.

investing.com2 min
AUG 24
$PTCTMedAI 8/10

PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction

PTC Therapeutics won a bankruptcy auction for Sangamo Therapeutics' Fabry disease gene therapy, ST-920, paying $111M upfront and up to $100M in milestones. PTC outbid Astellas and TerSera. The deal requires court and regulatory approval. ST-920 showed positive clinical data, supporting an accelerated FDA approval pathway. Eli Lilly also acquired other Sangamo assets for $50M.

cgtlive.com3 min
AUG 13
$PTCTMedAI 9/10

PTC Expands Rare Disease Portfolio With ST-920 Acquisition

PTC Therapeutics (PTCT) agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upfront plus milestones. PTC cites Phase 1/2 STAAR data and plans an accelerated approval BLA submission, with CMC due Q4 2026 and a 2027 launch. Close expected in Q3 2026.

rttnews.com4 min